Lung Cancer | Norton Healthcare

Indication: Lung Cancer

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Sta

Sub-indication: Lung Cancer

Drug Study

Principal Investigator: Adam Lye, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Email for more information: Lung-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.